# Biotech Daily Digest ‚Äî 2025-09-26

**38 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 4 items
- Endpoints News: 9 items
- Fierce Biotech: 7 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 17 items


## Eli Lilly Press Releases

- **[Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem](https://investor.lilly.com/news-releases/news-release-details/lilly-opens-newest-gateway-labs-site-san-diego-boost-local)**  
  _Fri, 26 Sep 2025 08:30:00 -0400_  
  New 82,514 square foot facility will accommodate up to 15 biotech companies to fuel next-generation medicines¬† Gateway Labs model provides flexible lab space and tailored scientific engagement to support early-stage biotechs INDIANAPOLIS , Sept. 26, 2025 /PRNewswire/ -- Eli Lilly and Company

- **[Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease](https://investor.lilly.com/news-releases/news-release-details/lillys-kisunla-donanemab-receives-marketing-authorization-0)**  
  _Thu, 25 Sep 2025 18:39:00 -0400_  
  Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS , Sept.

- **[U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer](https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-inluriyo-imlunestrant-adults-er-her2-esr1)**  
  _Thu, 25 Sep 2025 14:01:00 -0400_  
  An estimated 50% of patients with ER+, HER2 ‚Äì metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo monotherapy reduced the risk of progression or death by 38% versus endocrine therapy among patients with

- **[Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas](https://investor.lilly.com/news-releases/news-release-details/lilly-plans-build-new-65-billion-facility-manufacture-active)**  
  _Tue, 23 Sep 2025 13:00:00 -0400_  
  The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines¬† Company plans to create 4,615 manufacturing and construction jobs INDIANAPOLIS , Sept. 23, 2025 /PRNewswire/ -- Eli Lilly and Company


## Endpoints News

- **[Get your CVR: Backloaded acquisitions come into focus following Metsera, 89bio deals](https://endpoints.news/get-your-cvr-backloaded-acquisitions-come-into-focus-following-metsera-89bio-deals/)**  
  _Fri, 26 Sep 2025 13:30:47 +0000_  
  As pharma companies become even more risk-averse, biotechs that have been getting acquired are increasingly finding that for shareholders to get the full deal value, their assets must reach their promised potential.

 Two major deals ...

- **[Merck KGaA‚Äôs top-level changes continue with CEO transition; Incyte hires strategy exec](https://endpoints.news/merck-kgaas-top-level-changes-continue-with-ceo-transition-incyte-hires-strategy-exec/)**  
  _Fri, 26 Sep 2025 11:00:12 +0000_  
  ‚Üí Major personnel moves have been a recurring theme at Merck KGaA in recent months, and there are none bigger than CEO Bel√©n Garijo‚Äôs upcoming departure. On May 1, 2026, Garijo

- **[FDA approves Lilly's oral SERD in second-line breast cancer](https://endpoints.news/fda-approves-lillys-oral-serd-in-second-line-breast-cancer/)**  
  _Thu, 25 Sep 2025 19:23:52 +0000_  
  The FDA on Thursday approved Eli Lilly‚Äôs imlunestrant, an oral SERD, to treat patients with a certain kind of breast cancer.

 The drug will be branded as Inluriyo and is approved ...

- **[Novartis escalates court fight against Maine 340B law](https://endpoints.news/novartis-escalates-court-fight-against-maine-340b-law/)**  
  _Thu, 25 Sep 2025 19:02:51 +0000_  
  The fight over the use of ‚Äúcontract pharmacies‚Äù in the 340B drug discount program has reached another federal appeals court.

 Novartis asked the US Court of Appeals for the First Circuit this week to review ...

- **[Post-Hoc Live: How the US can compete with China biotech, with Scott Gottlieb](https://endpoints.news/post-hoc-live-how-the-us-can-compete-with-china-biotech-with-scott-gottlieb/)**  
  _Thu, 25 Sep 2025 18:51:41 +0000_  
  Over the last few months on Post-Hoc Live, we‚Äôve done shows about the rapid rise of China‚Äôs biotech industry, and how some in the industry are pushing for restrictions to block or slow competition. Today ...

- **[Biogen calls it quits on AAV gene therapy, again](https://endpoints.news/biogen-calls-it-quits-on-aav-gene-therapy-again/)**  
  _Thu, 25 Sep 2025 18:33:19 +0000_  
  Biogen is ending its gene therapy work that relies on adeno-associated viruses, or AAVs, the company confirmed to Endpoints News, making it the latest pharma to walk away from the viral-based delivery technology in recent ...

- **[Kardigan gets the rights to a MyoKardia drug; Lilly stops Phase 2 trial for muscle-sparing candidate](https://endpoints.news/kardigan-gets-the-rights-to-a-myokardia-drug-lilly-stops-phase-2-trial-for-muscle-sparing-candidate/)**  
  _Thu, 25 Sep 2025 15:29:36 +0000_  
  Plus, news about uniQure, MBX Biosciences, KalVista, Volastra, Basilea Pharmaceutica, Gossamer Bio, Respira Therapeutics, Sanofi, Immuneering and Heidelberg Pharma:

 ü´Ä Kardigan reveals its pipeline: The cardiovascular biotech has in-licensed three clinical-stage assets for undisclosed terms ...

- **[Catalent moves into new HQ; Fujifilm opens factory in North Carolina](https://endpoints.news/catalent-moves-into-new-hq-fujifilm-opens-factory-in-north-carolina/)**  
  _Thu, 25 Sep 2025 15:10:57 +0000_  
  Welcome to Endpoints News‚Äô manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

 Catalent opened its new headquarters in Tampa, FL, on Monday. Earlier this ...

- **[Pfizer's Metsera deal could spark more M&A for pharmas 'tiptoeing into obesity'](https://endpoints.news/pfizers-metsera-deal-could-spark-more-ma-for-pharmas-tiptoeing-into-obesity/)**  
  _Thu, 25 Sep 2025 14:58:48 +0000_  
  Pfizer's up to $7.3 billion acquisition of Metsera earlier this week was the first big pharma purchase of an obesity biotech since Roche‚Äôs buyout of Carmot Therapeutics in late 2023.

 Analysts told Endpoints News they ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-opens-latest-incubator-site-san-diego-several-biotechs-already-board" hreflang="en">Eli Lilly opens incubator site in San Diego, with 'several' biotechs already on board</a>](https://www.fiercebiotech.com/biotech/lilly-opens-latest-incubator-site-san-diego-several-biotechs-already-board)**  
  _Sep 26, 2025 9:33am_  
  While Eli Lilly is rethinking its biotech incubator plans in Europe, the Big Pharma has gone ahead and opened its San Diego site.

- **[<a href="https://www.fiercebiotech.com/biotech/fierce-biotechs-fierce-15" hreflang="en">Fierce Biotech's Fierce 15</a>](https://www.fiercebiotech.com/biotech/fierce-biotechs-fierce-15)**  
  _Sep 26, 2025 9:00am_  
  In this episode of "The Top Line," we discuss what went into picking this year‚Äôs Fierce 15 winners and some highlights from the special report.

- **[<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-merck-kgaa-picks-new-pilot-turbulent-times" hreflang="en">Chutes &amp; Ladders‚ÄîMerck KGaA picks new pilot for turbulent times</a>](https://www.fiercebiotech.com/biotech/chutes-ladders-merck-kgaa-picks-new-pilot-turbulent-times)**  
  _Sep 25, 2025 5:00pm_  
  Bel√©n Garijo, who steered the German healthcare and electronics conglomerate through the COVID-19 pandemic, will step down as CEO in April 2026. Kai Beckmann, currently the firm's CEO of electronics, will succeed her as the new group CEO on May 1, 2026.

- **[<a href="https://www.fiercebiotech.com/biotech/us-biotechs-think-twice-about-licensing-drugs-europe-over-pricing-controversies" hreflang="en">US biotechs think twice about EU licensing deals amid Trump's drug pricing campaign</a>](https://www.fiercebiotech.com/biotech/us-biotechs-think-twice-about-licensing-drugs-europe-over-pricing-controversies)**  
  _Sep 26, 2025 5:51am_  
  U.S. biotechs are increasingly reluctant to license their drugs to European partners in order to avoid becoming a target of the Trump administration, industry insiders have told Fierce Biotech.

- **[<a href="https://www.fiercebiotech.com/medtech/trump-administration-launches-tariff-probe-medtech-industry" hreflang="en">Trump administration launches tariff probe into medtech industry</a>](https://www.fiercebiotech.com/medtech/trump-administration-launches-tariff-probe-medtech-industry)**  
  _Sep 25, 2025 2:18pm_  
  Known as a Section 232 investigation, the Commerce Department's work will cover everything from MRIs, robots and pacemakers to syringes, masks and gloves.

- **[<a href="https://www.fiercebiotech.com/biotech/nih-earmarks-87m-new-organoid-center-pivot-away-animal-testing-continues" hreflang="en">NIH earmarks $87M for new organoid center as pivot away from animal testing continues</a>](https://www.fiercebiotech.com/biotech/nih-earmarks-87m-new-organoid-center-pivot-away-animal-testing-continues)**  
  _Sep 25, 2025 11:42am_  
  The National Institutes of Health is continuing its mission to reduce the use of animals in drug testing by awarding $87 million in contracts to launch the Standardized Organoid Modeling (SOM) Center, the agency announced in a Sept. 25 release.

- **[<a href="https://www.fiercebiotech.com/regulatory/republicans-unveil-7-week-stopgap-hospital-funding-telehealth-extensions-no-aca-premiums" hreflang="en">White House preps agencies for mass layoffs if government shuts down: media reports</a>](https://www.fiercebiotech.com/regulatory/republicans-unveil-7-week-stopgap-hospital-funding-telehealth-extensions-no-aca-premiums)**  
  _Sep 16, 2025 2:53pm_  
  Oft-extended programs for safety-net hospitals and regulatory flexibilities around virtual care are in flux as party leaders spar on other healthcare items like ACA subsidies.


## Regeneron Press Releases

- **[Evkeeza¬Æ (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol](https://investor.regeneron.com/news-releases/news-release-details/evkeezar-evinacumab-dgnb-angptl3-antibody-approved-us-children)**  
  _Fri, 26 Sep 2025 07:00:00 -0400_  
  FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) Initial Evkeeza approval based on placebo-controlled trial


## arXiv q-bio

- **[cAItomorph: Transformer-Based Hematological Malignancy Prediction from Peripheral Blood Smears in a Real-Word Cohort](https://arxiv.org/abs/2509.20402)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.20402v1 Announce Type: new 
Abstract: Peripheral blood smears remain a cornerstone in the diagnosis of hematological neoplasms, offering rapid and valuable insights that inform subsequent diagnostic steps. However, since neoplastic transformations typically arise in the bone marrow, they may not manifest as‚Ä¶

- **[Pattern Formation in Agent-Based and PDE Models for Evolutionary Games with Payoff-Driven Motion](https://arxiv.org/abs/2509.20538)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.20538v1 Announce Type: new 
Abstract: Spatial structure can play an important role in the evolution of cooperative behavior and the achievement of collective success of a population. In this paper, we explore the role of random and directed motion on spatial pattern formation and the payoff achieved by popu‚Ä¶

- **[Data-driven Neural Networks for Windkessel Parameter Calibration](https://arxiv.org/abs/2509.21206)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.21206v1 Announce Type: new 
Abstract: In this work, we propose a novel method for calibrating Windkessel (WK) parameters in a dimensionally reduced 1D-0D coupled blood flow model. To this end, we design a data-driven neural network (NN)trained on simulated blood pressures in the left brachial artery. Once t‚Ä¶

- **[A Hierarchical Adaptive Diffusion Model for Flexible Protein-Protein Docking](https://arxiv.org/abs/2509.20542)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.20542v1 Announce Type: cross 
Abstract: Structural prediction of protein-protein interactions is important to understand the molecular basis of cellular interactions, but it still faces major challenges when significant conformational changes are present. We propose a generative framework of hierarchical ad‚Ä¶

- **[Learning to Align Molecules and Proteins: A Geometry-Aware Approach to Binding Affinity](https://arxiv.org/abs/2509.20693)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.20693v1 Announce Type: cross 
Abstract: Accurate prediction of drug-target binding affinity can accelerate drug discovery by prioritizing promising compounds before costly wet-lab screening. While deep learning has advanced this task, most models fuse ligand and protein representations via simple concatenat‚Ä¶

- **[Incorporating LLM Embeddings for Variation Across the Human Genome](https://arxiv.org/abs/2509.20702)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.20702v1 Announce Type: cross 
Abstract: Recent advances in large language model (LLM) embeddings have enabled powerful representations for biological data, but most applications to date focus only on gene-level information. We present one of the first systematic frameworks to generate variant-level embeddin‚Ä¶

- **[A Genetic Algorithm for Navigating Synthesizable Molecular Spaces](https://arxiv.org/abs/2509.20719)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.20719v1 Announce Type: cross 
Abstract: Inspired by the effectiveness of genetic algorithms and the importance of synthesizability in molecular design, we present SynGA, a simple genetic algorithm that operates directly over synthesis routes. Our method features custom crossover and mutation operators that‚Ä¶

- **[Detecting gene-environment interactions to guide personalized intervention: boosting distributional regression for polygenic scores](https://arxiv.org/abs/2509.20850)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.20850v1 Announce Type: cross 
Abstract: Polygenic risk scores can be used to model the individual genetic liability for human traits. Current methods primarily focus on modeling the mean of a phenotype neglecting the variance. However, genetic variants associated with phenotypic variance can provide importa‚Ä¶

- **[Cross-Linguistic Analysis of Memory Load in Sentence Comprehension: Linear Distance and Structural Density](https://arxiv.org/abs/2509.20916)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.20916v1 Announce Type: cross 
Abstract: This study examines whether sentence-level memory load in comprehension is better explained by linear proximity between syntactically related words or by the structural density of the intervening material. Building on locality-based accounts and cross-linguistic evide‚Ä¶

- **[Not All Accuracy Is Equal: Prioritizing Diversity in Infectious Disease Forecasting](https://arxiv.org/abs/2509.21191)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.21191v1 Announce Type: cross 
Abstract: Ensemble forecasts have become a cornerstone of large-scale disease response, underpinning decision making at agencies such as the US Centers for Disease Control and Prevention (CDC). Their growing use reflects the goal of combining multiple models to improve accuracy‚Ä¶

- **[SlideMamba: Entropy-Based Adaptive Fusion of GNN and Mamba for Enhanced Representation Learning in Digital Pathology](https://arxiv.org/abs/2509.21239)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2509.21239v1 Announce Type: cross 
Abstract: Advances in computational pathology increasingly rely on extracting meaningful representations from Whole Slide Images (WSIs) to support various clinical and biological tasks. In this study, we propose a generalizable deep learning framework that integrates the Mamba‚Ä¶

- **[Multimodal AI predicts clinical outcomes of drug combinations from preclinical data](https://arxiv.org/abs/2503.02781)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2503.02781v2 Announce Type: replace 
Abstract: Predicting clinical outcomes from preclinical data is essential for identifying safe and effective drug combinations, reducing late-stage clinical failures, and accelerating the development of precision therapies. Current AI models rely on structural or target-based‚Ä¶

- **[Flexible MOF Generation with Torsion-Aware Flow Matching](https://arxiv.org/abs/2505.17914)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2505.17914v2 Announce Type: replace 
Abstract: Designing metal-organic frameworks (MOFs) with novel chemistries is a longstanding challenge due to their large combinatorial space and complex 3D arrangements of the building blocks. While recent deep generative models have enabled scalable MOF generation, they ass‚Ä¶

- **[Interpretable Embeddings of Speech Enhance and Explain Brain Encoding Performance of Audio Models](https://arxiv.org/abs/2507.16080)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2507.16080v2 Announce Type: replace 
Abstract: Speech foundation models (SFMs) are increasingly hailed as powerful computational models of human speech perception. However, since their representations are inherently black-box, it remains unclear what drives their alignment with brain responses. To remedy this, w‚Ä¶

- **[A Quotient Homology Theory of Representation in Neural Networks](https://arxiv.org/abs/2502.01360)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2502.01360v3 Announce Type: replace-cross 
Abstract: Previous research has proven that the set of maps implemented by neural networks with a ReLU activation function is identical to the set of piecewise linear continuous maps. Furthermore, such networks induce a hyperplane arrangement splitting the input domain‚Ä¶

- **[A Compartmental Model for Epidemiology with Human Behavior and Stochastic Effects](https://arxiv.org/abs/2507.01046)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2507.01046v3 Announce Type: replace-cross 
Abstract: We propose a compartmental model for epidemiology wherein the population is split into groups with either comply or refuse to comply with protocols designed to slow the spread of a disease. Parallel to the disease spread, we assume that noncompliance with prot‚Ä¶

- **[ML-PWS: Estimating the Mutual Information Between Experimental Time Series Using Neural Networks](https://arxiv.org/abs/2508.16509)**  
  _Fri, 26 Sep 2025 00:00:00 -0400_  
  arXiv:2508.16509v2 Announce Type: replace-cross 
Abstract: The ability to quantify information transmission is crucial for the analysis and design of natural and engineered systems. The information transmission rate is the fundamental measure for systems with time-varying signals, yet computing it is extremely challen‚Ä¶
